AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Organ Medicine Article
PDF (399 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Original Article | Open Access

Basiliximab for the Treatment of Acute T‐Cell Mediated Rejection After Kidney Transplantation: Case Series and Preliminary Experience

Tingting Chen1, Lifei Liang2,3, Siyue Chen2,3, Qing Xu1, Xiaoyu Li1, Ming Xu2,3, Ruiming Rong2,3,4, Tongyu Zhu2,3,5 ( ), Cheng Yang2,3,6 ( )
Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China
Department of Kidney Transplantation, Zhongshan Hospital, Fudan University, Shanghai, China
Shanghai Key Laboratory of Organ Transplantation, Shanghai, China
Department of Transfusion, Zhongshan Hospital, Fudan University, Shanghai, China
Shanghai Medical College, Fudan University, Shanghai, China
Zhangjiang Institute of Fudan University, Shanghai, China

Tingting Chen, Lifei Liang, and Siyue Chen contributed equally to this work.

Show Author Information

Abstract

Background

The study aims to evaluate the preliminary efficacy and safety of basiliximab in treating acute T cell‐mediated rejection (TCMR) after kidney transplantation, particularly in patients with poor responses to standard treatments.

Methods

We conducted a retrospective case series study involving eight kidney transplant recipients at Zhongshan Hospital, Fudan University, who received basiliximab for anti‐TCMR treatment. Baseline characteristics, immunosuppression management data, and treatment outcomes were collected.

Results

Among the eight patients, two had biopsy‐proven TCMR. Elevated serum soluble IL‐2R (sIL‐2R) level were detected in all patients before basiliximab treatment. Following basiliximab therapy, all patients exhibited a rapid decrease in sIL‐2R levels, and most cases showed a general downward trend in serum creatinine levels. Although two patients developed pulmonary infections posttreatment, no clear correlation was found between the use of basiliximab and infections. No other new infections or adverse reactions were reported.

Conclusions

Basiliximab therapy demonstrates efficacy and good tolerance in patients with TCMR.

Graphical Abstract

Keywords

basiliximabIL‐2 receptor antagonistkidney transplantationT cell‐mediated rejection

References

【1】
【1】
 
 
Crossref Google Scholar
Organ Medicine
Volume 2 Issue 1,
March 2025
Pages 31-40
DOI: 10.1002/orm2.70002

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Cite this Report
Close
Close
Cite this article:
Chen T, Liang L, Chen S, et al. Basiliximab for the Treatment of Acute T‐Cell Mediated Rejection After Kidney Transplantation: Case Series and Preliminary Experience. Organ Medicine, 2025, 2(1): 31-40. https://doi.org/10.1002/orm2.70002

1048

Views

110

Downloads

1

Crossref
Received: 22 January 2025
Revised: 20 February 2025
Accepted: 26 February 2025
Published: 25 March 2025
© 2025 The Author(s).

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.